The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant attention within the United Kingdom , prompting a notable shift in hormone trends. Access these treatments remains a complex landscape, with NHS coverage currently limited and private clinics offering treatment at a premium . Concerns are being ra